YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Gilead Sciences (NASDAQ: GILD) has shifted from a period of stagnant growth, driven by slowing hepatitis C revenues and declining sales of its COVID-19 therapy Veklury, to a turnaround led by new HIV and oncology drugs. The pharmaceutical…
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision trigge…
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron…
* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.…
MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today…
Sanofi SA (NASDAQ:SNY) is one of the best dividend stocks yielding at least 5% to buy according to hedge funds. On June 22, Sanofi SA (NASDAQ:SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President and…
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. "Today's news…
Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Covering Development through Commercial Supply TAIPEI, TAIWAN / ACCESS Newswire / July 2, 2026 / Bora Pharmaceuticals Co., Ltd. ("Bo…
MacroGenics, Inc. ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and B…
(RTTNews) - MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company, announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the recently granted U.S. Food and Drug Administration's (F…
MacroGenics, Inc. ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today…
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it…
Sanofi SNY announced that the FDA has approved its type I diabetes (T1D) drug, Tzield (teplizumab), for a new indication under the accelerated pathway. The agency has cleared the therapy to delay the loss of the body's own insulin producti…
By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abstract acceptance at the 2026 American Society o…
Medtronic MDT is set to release fourth-quarter fiscal 2026 results on June 3, before the market opens. The company posted earnings per share (EPS) of $1.36 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 2.26%…
MacroGenics, Inc. ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that…
Shares of Harmonic Inc(NASDAQ:HLIT) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Also, the company raised its FY26 EP…
medical research 8 ©PickPik MacroGenics agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals in a deal designed to strengthen its balance sheet and sharpen focus on its oncology pipeline. Key Investor Takeaways MacroGeni…
(RTTNews) - MacroGenics, Inc. (MGNX) has entered into a definitive agreement to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd (6472.TW), with Bora paying $122.5 million upfront upon closing. The deal…
* MacroGenics (MGNX [https://seekingalpha.com/symbol/MGNX]) said [https://seekingalpha.com/pr/20510112-macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals] on Monday it agreed to sell its GMP drug substance manufacturi…
MacroGenics, Inc. •MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSW…
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) -- MacroGenic…
Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago. These figures are adjusted for non-recurring items. Th…
MacroGenics, Inc. • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million ROCKVILLE, MD, May 04, 2026 (GLOBE…
Sanofi SNY announced that the FDA has approved the supplemental biologic license application (sBLA) seeking to expand the use of Tzield (teplizumab) to delay the onset of stage 3 T1D in individuals aged one year and older with stage 2 dise…
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. MacroGenics, Inc. is one of the best biotech stocks. TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 pric…
(RTTNews) - MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company, announced that the U. S. Food and Drug Administration (FDA) has removed the partial clinical hold on the firm's Phase 2 LINNET study of Lorigerlimab in ovari…
The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong fi…
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, region…
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Neuroblastoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The neuroblastoma market has witnessed significant growth, projected to expand from $3.14 billion in 202…
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a first-in-class TOP1i-based ADC, on trac…
[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY [https://seekingalpha.com/symbol/INCY]) and MacroGe…
March S&P 500 E-Mini futures (ESH26) are trending down -0.53% this morning as Treasury yields continued to rise after another surge in oil prices stoked concerns that the Middle East conflict would drive inflation higher. The 10-year T-not…
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s man…
(RTTNews) - MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company announced that the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study evaluating lorigerlimab in gynecolo…
ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that th…